The 340B Hustle
How nonprofit hospitals turn discount drugs into big profits, and why no one knows where the money goes.
2024 Purchases
$81.4B
at 340B acquisition price
Gross Margin
$66.4B
available to covered entities
Growth Rate
23.5%
CAGR 2015-2024
Contract Pharmacies
33,000
194,016 relationships
The 340B Drug Pricing Program is a federal mandate requiring pharmaceutical manufacturers to sell outpatient drugs at significantly discounted prices to eligible healthcare organizations called "covered entities." The spread between a hospital's acquisition cost and its insurance reimbursement rate is kept by the covered entity as profit. No federal law requires that profit to be passed on to patients, directed toward charity care, or disclosed publicly. The program now surpasses Medicaid's total net prescription drug spending.
How 340B Works
A program designed to help safety-net hospitals stretch scarce resources has become the second-largest federal drug program in America.
The Spread: How the Money Flows
Illustrative example for a specialty drug (61.5% of total 340B spending):
Per prescription. Source: Drug Channels Institute; Senate HELP Committee Report, May 2025
Key Milestones
Program Scale (2024)
Covered Entity Sites
50,000+
Hospital Participants
2,600+
>40% of all U.S. hospitals
Federal Rank
2nd Largest
behind Medicare Part D only
WAC Value
$147.8B
list price of 2024 purchases
Who Benefits
DSH hospitals capture 80% of 340B revenue. Contract pharmacies skim dispensing and TPA fees. PBMs profit from specialty drug margins. The patient pays coinsurance on list price.
The Biggest Beneficiaries
| Entity | Detail | Source |
|---|---|---|
| Cleveland Clinic | $933.7M in 340B revenue (2020-2023). No direct patient discount requirement. | Senate HELP Committee, 2025 |
| Bon Secours Mercy Health | $276.5M from Richmond Community Hospital alone (2018-2023). 'Revenue is revenue.' | Senate HELP; NYT investigation |
| NYU Langone Health | 0.34% of $7.2B revenue on charity care. Spent $8M on a Super Bowl ad. | Third Way analysis |
| Univ. of Arkansas Medical Sciences | Sued 8,000+ patients for unpaid bills (2019-2023) while participating in 340B. | Third Way |
| Minnesota DSH Hospitals | Net 340B revenue of $630M in 2023. First state-level disclosure in the nation. | MN Dept. of Health, 2024 |
Contract Pharmacy Chains
CVS and Walgreens each disclosed $150-250M in annual profit exposure from 340B contract pharmacy changes.
The PBM Layer
The three largest PBMs (Express Scripts/Cigna, OptumRx/UnitedHealth, CVS Caremark) collectively have about 230 mail, specialty, and infusion pharmacy locations acting as 340B contract pharmacies, with nearly 43,000 relationships with covered entities.
The circular logic: Hospitals use 340B to generate margin. PBM-owned pharmacies skim dispensing and TPA fees. Commercial insurance plans pay inflated reimbursement that funds the spread. Insured patients pay coinsurance based on list price, not 340B price. Every node in the chain profits except the patient.
340B Revenue vs. Charity Care
85% of DSH hospitals received more from 340B profit than they invested in charity care in 2022.
2022 DSH 340B Gain
$44.1B
2022 DSH Charity Care
$18.5B
The Gap
$25.6B
Charity care as a percentage of patient costs at 340B DSH hospitals declined from 3.3% (2011) to 2.7% (2017) during a period when 340B purchases grew by over 100%. In 18 states and the District of Columbia, all disproportionate share hospitals earned more in 340B than they spent on charity care. Across 47 states and DC, over half of DSH hospitals earned more in 340B than they spent on charity care.
Source: Alliance for Integrity and Reform of 340B / Avalere Health, March 2024
HRSA Audit Findings
Zero terminations. Despite these findings, no covered entities were terminated from the 340B program. HRSA audits only ~200 of 50,000+ sites per year (coverage rate under 0.5%).
GAO & OIG Findings
GAO (2018)
57% of hospitals did not provide discounted prices to low-income, uninsured patients at contract pharmacies.
GAO (2019)
HRSA oversight inadequate. Recommended 20 improvements. As of 2023, only 5 implemented.
OIG (2014)
Two out of three hospitals did not offer 340B discounted prices to uninsured patients via contract pharmacies.
CBO (Sept 2025)
340B program is costing taxpayers. No evidence patients are benefitting.
340B Hospital Margins vs. Non-340B
JAMA 2024 Study (Harris)
Analysis of >400,000 patients with BCBS insurance receiving infused drugs:
340B hospitals kept
64%
of price charged
Non-340B hospitals kept
44%
of price charged
Operating Margins (2021)
One-fifth of 340B hospitals had operating margins of nearly 21%. For comparison, the average among non-340B hospitals was about 6%.
Top 340B hospitals
~21%
Non-340B average
~6%
CON + 340B + Tax Exemption
The convergence point that the establishment does not want discussed openly.
When a CON-protected nonprofit DSH hospital also participates in 340B:
It has legally blocked competitors from entering its market
It qualifies for 340B based on its inpatient Medicaid/low-income population, but most 340B purchases occur in its outpatient facilities, which can be anywhere in the state
It can open 340B-eligible 'child site' outpatient clinics in wealthy suburbs (where the commercially insured patients are) while qualifying via the poor urban core
The drug spread from those suburban oncology clinics flows back to the parent system with no accountability
The result: CON + 340B + nonprofit tax exemption creates a legally sanctioned, vertically integrated extraction machine. The poor neighborhood justifies the eligibility. The wealthy suburb generates the margin. The nonprofit status shields the profit. No disclosure required.
The Subsidy Stack
A single large DSH teaching hospital can simultaneously receive all five of these subsidies. There is no federal mechanism that prevents it. There is no disclosure requirement connecting them.
| Subsidy | Source | Purpose |
|---|---|---|
| DSH Payments | Medicare/Medicaid | Uncompensated care for low-income patients |
| 340B Drug Discounts | HRSA/OPA | Cheap drugs for 'safety-net' outpatient care |
| GME/IME Payments | Medicare | Graduate medical education and teaching overhead |
| Nonprofit Tax Exemption | IRS/State | Federal + state tax relief for 'community benefit' |
| CON Protection | State | Blocked competitor entry |
The Nonprofit Tax Exemption Circularity
A hospital qualifies for 340B by treating Medicaid patients. It claims the unreimbursed cost of treating those same Medicaid patients as "community benefit" to justify its tax exemption. It then uses 340B revenue to subsidize operations and expansion. The Medicaid patient has now justified three separate federal/state subsidies: 340B discounts, DSH payments, and tax exemption, while potentially being billed full price for their prescriptions.
According to the Lown Institute Hospitals Index, 77% of nonprofit hospitals had a fair share deficit, meaning they spent less on charity care and community investment than the value of their tax exemption.
Lawsuits & Scandals
From the Supreme Court to federal district courts, 340B litigation is reshaping the program.
AHA v. Becerra (2022)
Supreme Court ruled unanimously that HHS's 2018-2019 cuts to 340B hospital reimbursement rates were unlawful because HHS failed to conduct the required survey of hospitals' acquisition costs.
AHA v. Kennedy (D. Maine, Feb 2026)
U.S. District Court vacated and remanded the 340B Rebate Model Pilot Program. HHS is reconsidering whether to implement a rebate model consistent with its statutory authority.
DOJ v. Methodist Le Bonheur (2022)
United States filed suit against Methodist Le Bonheur Healthcare for alleged 340B program violations.
PhRMA v. Murrill (W.D. Louisiana, 2024)
PhRMA, AstraZeneca, and AbbVie sued Louisiana AG over contract pharmacy access law. District court ruled for the state. Appealed to Fifth Circuit; no ruling yet.
J&J v. HHS (D.D.C., Nov 2024)
J&J sued HHS asserting its rebate model complied with 340B statute. Multiple manufacturers (Eli Lilly, BMS) filed similar suits. All in early stages.
Senate HELP Committee (Cassidy, 2023-2025)
Multi-year investigation into Bon Secours, Cleveland Clinic, CVS, Walgreens, Eli Lilly, and others. Report released May 2025. Called for congressional action on transparency and charity care requirements.
The Reform Landscape
Federal legislation, state transparency laws, and manufacturer restrictions are converging on the 340B program.
340B ACCESS Act (H.R. 5256)
Sponsors: Rep. Buddy Carter (R-GA) and Diana Harshbarger (R-TN) | Introduced Sept 10, 2025
State-Level Action
In 2025, 13 states enacted 340B contract pharmacy access laws and 7 states passed provider reporting requirements.
Minnesota
First state nationally with mandatory 340B revenue disclosure. 2023 data published November 2024.
Contract Pharmacy Access States (13)
AR, LA, MD, MN, MS, MO, SD, WV, HI, TN, and others
HHS FY2026 Budget
Proposes moving 340B administration from HRSA to CMS
The Rojas Report Take
$66.4 billion in gross margin. Zero disclosure requirements. This is not a safety net. This is the architecture of capture.
The 340B program was designed in 1992 to help safety-net hospitals stretch scarce resources. It has since grown into a $147.8 billion extraction machine that now surpasses Medicaid's total net prescription drug spending. The program has grown at 23.5% annually for a decade. No one knows where the money goes.
The strongest honest defense of 340B is real: safety-net hospitals operate on razor-thin margins, and without 340B revenue, many rural hospitals and community health centers would close. The AHA's data point that 340B hospitals deliver 77% of all Medicaid hospital care is not wrong. But that statistic covers all 340B hospitals, while DSH hospitals capturing 80% of the money are increasingly wealthy, high-margin systems, not rural safety nets.
The convergence of 340B + CON laws + nonprofit tax exemption creates a legally sanctioned subsidy stack with no accountability. A hospital can simultaneously block competitors through CON, buy drugs at 75% discounts through 340B, avoid taxes through nonprofit status, and claim "community benefit" by counting the unreimbursed cost of treating the same Medicaid patients who qualified it for the program in the first place. The Bon Secours investigation in Richmond proved this is not theoretical. It is the business model.
340B is not a bug. It is the whole system working as designed by the people who designed it.
— The Rojas Report
Continue the Investigation
National Overview
50-State CON Rankings
35 jurisdictions still enforce CON laws. Interactive table with scores, tiers, and reform status.
State Profile
Kentucky
Score 100. Three systems control 100% of Louisville's inpatient market. Prices reach 354% of Medicare.
State Profile
Virginia
Score 100. Bon Secours Richmond: the documented case study of CON + 340B extraction.
Sources: HRSA OPA; Drug Channels Institute; CBO; GAO; OIG; Senate HELP Committee (Cassidy, 2025); Alliance for Integrity and Reform of 340B / Avalere Health; IQVIA; Minnesota Department of Health; JAMA 2024 (Harris); Third Way; Lown Institute; Community Oncology Alliance; Federal Register; 340B Report. All data verified as of March 2026.